AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33472389 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 99
Study 33472389 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 99
Study 33472389 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 99
Study 33472389 — intervention group
Group type: COMPARATOR
Intervention: Clozapine vs Haloperidol in patients with conduct disorder
Number of subjects: 99
Study 33472389 — intervention group
Group type: COMPARATOR
Intervention: Clozapine vs Haloperidol in patients without conduct disorder
Number of subjects: 99
Study 33472389 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine vs Haloperidol in patients with conduct disorder
Number of subjects: 99
Study 35258802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, multicomponent word reading and reading comprehension intervention for 2 years
Number of subjects: 0
Study 35258802 — intervention group
Group type: COMPARATOR
Intervention: Business as usual (BaU)
Number of subjects: 0
Study 32378932 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention for alcohol use and PTSD (details on dosage and duration not available)
Number of subjects: 366
Study 36397390 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.06 mg/kg (M2)
Number of subjects: 102
Study 36397390 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam co-induction
Number of subjects: 102
Study 36397390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 102
Study 34462198 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatekeeper-referral
Number of subjects: 197
Study 34462198 — intervention group
Group type: COMPARATOR
Intervention: Self-referral
Number of subjects: 197
Study 34462198 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral by medical practitioners
Number of subjects: 197
Study 34462198 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated contact
Number of subjects: 197
Study 33768205 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 97
Study 33768205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 33356547 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterra Drug Deactivation System deactivation pouches
Number of subjects: 75
Study 33356547 — intervention group
Group type: COMPARATOR
Intervention: Standard opioid disposal instructions
Number of subjects: 75
Study 33831566 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (12.4 mmol NO3? per day)
Number of subjects: 12
Study 33831566 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation
Number of subjects: 12
Study 33831566 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted BR (placebo)
Number of subjects: 12
Study 36197494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 278
Study 36197494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 33499754 — intervention group
Group type: EXPERIMENTAL
Intervention: modified directly administered antiretroviral therapy (mDAART)
Number of subjects: 34
Study 33499754 — intervention group
Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 34
Study 34996695 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS intervention
Number of subjects: 7
Study 34996695 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 7
Study 34673536 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training (SG)
Number of subjects: 40
Study 34673536 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered high-intensity interval training guided by smartphone app (AG)
Number of subjects: 40
Study 32251068 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported progression assessment (aggregate cluster of questions)
Number of subjects: 0
Study 34766589 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/day of oral cholecalciferol (vitamin D)
Number of subjects: 40
Study 34766589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 40
Study 36120873 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging Mastery Program (AMP)
Number of subjects: 0
Study 36120873 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 32841433 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg pycnogenol taken orally twice a day for 60 days
Number of subjects: 44
Study 32841433 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken orally twice a day for 60 days
Number of subjects: 44
Study 616769481 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 20 mg IV
Number of subjects: 90
Study 616769481 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg and Ketorolac 10 mg IV
Number of subjects: 90
Study 33482699 — intervention group
Group type: EXPERIMENTAL
Intervention: vonapanitase
Number of subjects: 603
Study 33482699 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 603
Study 36247802 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (2/3 aerobic, high-intensity interval training sessions per week supervised by personal trainers)
Number of subjects: 1560
Study 36247802 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support (1 session per week at a local cancer support centre)
Number of subjects: 1560
Study 36247802 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and psychological support
Number of subjects: 1560
Study 36247802 — intervention group
Group type: COMPARATOR
Intervention: Usual pre-operative care (control group)
Number of subjects: 1560
Study 32203986 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-channel water exchange colonoscopy
Number of subjects: 120
Study 32203986 — intervention group
Group type: COMPARATOR
Intervention: One-channel water exchange colonoscopy
Number of subjects: 120
Study 35738656 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-enriched nutritional supplements (65 g/day)
Number of subjects: 72
Study 35738656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 32051513 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD) for 6 weeks
Number of subjects: 77
Study 32051513 — intervention group
Group type: COMPARATOR
Intervention: Gluten challenge (double-blind placebo controlled)
Number of subjects: 77
Study 32051513 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 77
Study 34128780 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Cognitive Stimulation (PCS) program for 10 weeks
Number of subjects: 50
Study 34128780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCS program)
Number of subjects: 50
Study 33092986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity otoscopy simulation
Number of subjects: 200
Study 33092986 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methods (Control)
Number of subjects: 200
Study 33092986 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire
Number of subjects: 200
Study 33092986 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation for curriculum inclusion
Number of subjects: 200
Study 33611847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 724
Study 33611847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 32211776 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative HBV RNA and HBcrAg < 4 log10 U/mL at end of treatment (EOT)
Number of subjects: 186
Study 32211776 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive HBV RNA and HBcrAg ≥ 4 log10 U/mL at EOT
Number of subjects: 186
Study 32211776 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative HBV RNA and HBcrAg < 4 log10 U/mL at EOT
Number of subjects: 186
Study 32211776 — intervention group
Group type: COMPARATOR
Intervention: Entecavir or tenofovir before discontinuation (validation cohort)
Number of subjects: 186
Study 36134780 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanized body weight check
Number of subjects: 30
Study 36134780 — intervention group
Group type: COMPARATOR
Intervention: Traditional body weight check
Number of subjects: 30
Study 35196064 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial reimbursement program (FRP) with follow-up telephone call
Number of subjects: 132
Study 35196064 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no follow-up)
Number of subjects: 132
Study 33991482 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal benefit information
Number of subjects: 15014
Study 33991482 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety concerns information
Number of subjects: 15014
Study 33991482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all information
Number of subjects: 15014
Study 33991482 — intervention group
Group type: COMPARATOR
Intervention: Control condition (safety and effectiveness statement from NHS)
Number of subjects: 15014
Study 35745211 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized 2S-Hesperidin (M2SH)
Number of subjects: 30
Study 35745211 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized Hesperidin epimeric mixture (MHEM)
Number of subjects: 30
Study 35745211 — intervention group
Group type: COMPARATOR
Intervention: Hesperidin epimeric mixture (HEM)
Number of subjects: 30
Study 33938939 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant weight-for-age z score at 12 months of age
Number of subjects: 294
Study 33938939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid weight gain from birth to 24 months of age
Number of subjects: 294
Study 33938939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid weight gain from birth to 3 months of age
Number of subjects: 294
Study 33938939 — intervention group
Group type: EXPERIMENTAL
Intervention: Length-related indicators during early life
Number of subjects: 294
Study 32549090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% lotion
Number of subjects: 1614
Study 32549090 — intervention group
Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 1614
Study 35307055 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (IVCV and Pcv-aCO2 monitoring)
Number of subjects: 80
Study 35307055 — intervention group
Group type: COMPARATOR
Intervention: Control group (EGDT strategy)
Number of subjects: 80
Study 34624047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle medicine group (LM group)
Number of subjects: 31
Study 34624047 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual group (CAU group)
Number of subjects: 31
Study 32344285 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone administration (levothyroxine and liothyronine)
Number of subjects: 0
Study 32344285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35312970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with luseogliflozin 2.5 mg once daily and semaglutide 0.5 mg once per week
Number of subjects: 60
Study 35312970 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with semaglutide
Number of subjects: 60
Study 34796735 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocoagulation tuboplasty
Number of subjects: 0
Study 34796735 — intervention group
Group type: COMPARATOR
Intervention: Continued medical therapy
Number of subjects: 0
Study 32826450 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-strut drug-eluting stent (DES)
Number of subjects: 50
Study 32826450 — intervention group
Group type: COMPARATOR
Intervention: Thick-strut drug-eluting stent (DES)
Number of subjects: 50
Study 33225901 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA-approved immune checkpoint inhibitors (ICIs)
Number of subjects: 42
Study 35714551 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (continued treatment for 7 weeks)
Number of subjects: 63
Study 35714551 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gradual withdrawal from methylphenidate for 7 weeks)
Number of subjects: 63
Study 33270526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian methods for statistical inference
Number of subjects: 0
Study 33270526 — intervention group
Group type: COMPARATOR
Intervention: Frequentist statistical approaches
Number of subjects: 0
Study 36396067 — intervention group
Group type: EXPERIMENTAL
Intervention: Coin2Dose intervention for 12 weeks followed by a 12-week maintenance period
Number of subjects: 0
Study 36396067 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 0
Study 34929355 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii therapy (interactive gaming, Nintendo Wii)
Number of subjects: 40
Study 34929355 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study 32915060 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic left pancreatectomy (RLP)
Number of subjects: 75
Study 32915060 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic left pancreatectomy (LLP)
Number of subjects: 75
Study 32187403 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion after exercise
Number of subjects: 9
Study 32187403 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion after exercise
Number of subjects: 9
Study 32187403 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Number of subjects: 9
Study 32187403 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 9
Study 33052030 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week exercise group
Number of subjects: 15
Study 33052030 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 35084243 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous moderate aerobic exercise (CE)
Number of subjects: 25
Study 35084243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 25
Study 32572617 — intervention group
Group type: EXPERIMENTAL
Intervention: EX + PRO (30 min low-moderate-intensity treadmill walking followed by 20 g whey protein)
Number of subjects: 12
Study 32572617 — intervention group
Group type: COMPARATOR
Intervention: EX (30 min low-moderate-intensity treadmill walking without whey protein)
Number of subjects: 12
Study 32572617 — intervention group
Group type: COMPARATOR
Intervention: CON (30 min rest)
Number of subjects: 12
Study 33433386 — intervention group
Group type: EXPERIMENTAL
Intervention: FA-TiO2-Pc (low dose)
Number of subjects: 0
Study 33433386 — intervention group
Group type: EXPERIMENTAL
Intervention: FA-TiO2-Pc (in vitro)
Number of subjects: 0
Study 33433386 — intervention group
Group type: EXPERIMENTAL
Intervention: FA-TiO2-Pc
Number of subjects: 0
Study 32466187 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous running exercise (CR) at 75% of VO2max for 25 min
Number of subjects: 13
Study 32466187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent running exercise #1 (15/15) at 75% of VO2max for 50 min
Number of subjects: 13
Study 32466187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent running exercise #2 (30/30) at 75% of VO2max for 50 min
Number of subjects: 13
Study 32280656 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied to the surgical site after polyp removal.
Number of subjects: 21
Study 32280656 — intervention group
Group type: COMPARATOR
Intervention: Control side (no PRP applied).
Number of subjects: 21
Study 35236735 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg olanzapine (OLZ) in combination with triple antiemetic therapy
Number of subjects: 500
Study 35236735 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with triple antiemetic therapy
Number of subjects: 500
Study 33636373 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 51
Study 33636373 — intervention group
Group type: COMPARATOR
Intervention: Sham Dry Needling (sham-DN)
Number of subjects: 51
Study 35998872 — intervention group
Group type: EXPERIMENTAL
Intervention: cathodal transcranial direct current stimulation (c‐tDCS)
Number of subjects: 10
Study 35998872 — intervention group
Group type: COMPARATOR
Intervention: placebo stimulus (sham)
Number of subjects: 10
Study 32202716 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao's 'xingnaofusu' needling and routine western medicine
Number of subjects: 50
Study 32202716 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 50
Study 32202716 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao's 'xingnaofusu' needling
Number of subjects: 50
Study 32202716 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine western medicine)
Number of subjects: 50
Study 35911085 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) <1 year after diagnosis
Number of subjects: 3608
Study 35911085 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients diagnosed in 2011
Number of subjects: 3608
Study 35911085 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 3608
Study 35911085 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason score ≥4 + 3
Number of subjects: 3608
Study 32975189 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream (Aldara) for up to 16 weeks
Number of subjects: 503
Study 32975189 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% podophyllotoxin cream (Warticon) for 4 weeks (extended to 16 weeks if warts persisted)
Number of subjects: 503
Study 32975189 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent human papillomavirus vaccine (Gardasil)
Number of subjects: 503
Study 32975189 — intervention group
Group type: COMPARATOR
Intervention: Saline control (placebo for HPV vaccine)
Number of subjects: 503
Study 32975189 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream (Aldara)
Number of subjects: 503
Study 32975189 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% podophyllotoxin cream (Warticon)
Number of subjects: 503
Study 36178015 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted optimization management (integration of usual care and traditional Chinese medicine treatment)
Number of subjects: 256
Study 36178015 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted optimization management
Number of subjects: 256
Study 36178015 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 256
Study 34411629 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 60
Study 34411629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34990772 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Citrulline (6 g/day)
Number of subjects: 16
Study 34878335 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry-based antibiotic susceptibility testing (MICy)
Number of subjects: 6
Study 32128859 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential stimulation
Number of subjects: 33
Study 32128859 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 33
Study 36033363 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training+ (GMT+)
Number of subjects: 48
Study 36033363 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation-control (Brain Health Workshop; BHW)
Number of subjects: 48
Study 32624568 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (12-week strength and endurance combined training program)
Number of subjects: 39
Study 32624568 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 39
Study 32624568 — intervention group
Group type: COMPARATOR
Intervention: Control group (obese children not receiving exercise training)
Number of subjects: 39
Study 33307192 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-field lymphadenectomy
Number of subjects: 400
Study 33307192 — intervention group
Group type: COMPARATOR
Intervention: Two-field lymphadenectomy
Number of subjects: 400
Study 33307192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 400
Study 33050913 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD)
Number of subjects: 80
Study 33050913 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Number of subjects: 80
Study 33050913 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 80
Study 35393772 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care intervention by trained nurses
Number of subjects: 84
Study 33722880 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 13480
Study 33722880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13480
Study 32722955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Number of subjects: 112
Study 32722955 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 112
Study 32722955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab and aflibercept
Number of subjects: 112
Study 35383975 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus and Bifidobacterium spp)
Number of subjects: 23
Study 35383975 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole (MET)
Number of subjects: 23
Study 35383975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 23
Study 32702778 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Decision Simulation (DDSim)
Number of subjects: 0
Study 32702778 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to DDSim)
Number of subjects: 0
Study 36454316 — intervention group
Group type: EXPERIMENTAL
Intervention: UINCARE Home+ (AR-based digital health care system)
Number of subjects: 100
Study 36454316 — intervention group
Group type: COMPARATOR
Intervention: Brochure-based home rehabilitation (Control)
Number of subjects: 100
Study 33509192 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDCS montage targeting dentate nuclei and anterior/posterior lobes
Number of subjects: 10
Study 33509192 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDCS montage targeting lower-limb representations (lobules VIIb-IX)
Number of subjects: 10